Cagrilintide* · Long-Acting Amylin Analogue*
Researchers seeking this product for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.
Cagrilintide is a long-acting synthetic analogue of amylin, a hormone involved in appetite regulation, gastric emptying, and glucose metabolism. Research has focused on its ability to influence satiety, food intake, body weight, and broader metabolic pathways.
Research Benefits
Appetite regulation research – Investigates amylin signaling involved in hunger and satiety.
Satiety & food-intake research – Studied for its ability to reduce food intake and influence meal-related signaling.
Body-weight research – Clinical studies have demonstrated substantial reductions in body weight in study participants.
Metabolic research – Investigated for effects involving glucose regulation, energy balance, and metabolic function.
Gastric emptying research – Provides a model for studying the relationship between gastric emptying, satiety, and post-meal glucose.
Combination research – Extensively studied in combination with semaglutide as CagriSema and other metabolic approaches.
Identified Risks & Side Effects
Gastrointestinal effects – Nausea, vomiting, and other gastrointestinal effects have been reported in clinical research.
Reduced appetite & food intake – Appetite suppression is an intended pharmacological effect that may influence nutritional intake.
Long-term safety remains under study – The long-term effects of cagrilintide continue to be evaluated.
Combination considerations – Research involving cagrilintide with other metabolic compounds requires careful evaluation of their combined effects.
Research material quality – Purity, identity, and analytical characterization are important considerations when evaluating research material.
Route: Experimental, varies by research protocol | Frequency: Varies by research protocol | FDA Status: Not FDA-approved
Researcher Note
Cagrilintide is an important research compound in the study of amylin biology, appetite regulation, and metabolic function. Its development as both a standalone compound and as part of CagriSema has generated substantial clinical research, making it particularly relevant to ongoing studies of next-generation approaches to weight and metabolic regulation.
Disclaimer
FDA Status: Not FDA-approved
Research Classification: Investigational / Research use only
Compound Type: Long-acting synthetic amylin analogue
All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.